Analysis

Sutro Biopharma, Inc. (STRO) Stock Analysis

Sutro Biopharma, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to STRO.

websiteSTRO/analysis/STRO

Sutro Biopharma, Inc.

Sutro Biopharma, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to STRO.

Stock profile

Ticker

STRO

Asset type

Stock

Market cap

$491.0M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Sutro Biopharma, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • STRO primary listing
  • S090
  • A41VMF

Latest Sutro Biopharma, Inc. news

Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights

– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 – – Continued a...

Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and ST...

Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – –

Sutro Biopharma Announces Participation at the 16th World ADC London Summit

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-spe...

Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-spe...

Research sections

Valuation

Review valuation context for Sutro Biopharma, Inc..

Future growth

Review future growth context for Sutro Biopharma, Inc..

Past performance

Review past performance context for Sutro Biopharma, Inc..

Financial health

Review financial health context for Sutro Biopharma, Inc..

Dividend

Review dividend context for Sutro Biopharma, Inc..

Management

Review management context for Sutro Biopharma, Inc..

Ownership

Review ownership context for Sutro Biopharma, Inc..

Other information

Review other information context for Sutro Biopharma, Inc..

Community

Review community context for Sutro Biopharma, Inc..